首页> 美国卫生研究院文献>British Journal of Clinical Pharmacology >Odanacatib a selective cathepsin K inhibitor to treat osteoporosis: safety tolerability pharmacokinetics and pharmacodynamics – results from single oral dose studies in healthy volunteers

【2h】

Odanacatib a selective cathepsin K inhibitor to treat osteoporosis: safety tolerability pharmacokinetics and pharmacodynamics – results from single oral dose studies in healthy volunteers

机译：Odanacatib一种选择性的组织蛋白酶K抑制剂可治疗骨质疏松症：安全性耐受性药代动力学和药效学–健康志愿者单次口服剂量研究的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

AimsTo evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of odanacatib (ODN), a cathepsin K inhibitor, in humans.

机译：目的评估组织蛋白酶K抑制剂odanacatib（ODN）在人体中的安全性，耐受性，药代动力学和药效学。

著录项

期刊名称 British Journal of Clinical Pharmacology
作者
S Aubrey Stoch; Stefan Zajic; Julie A Stone; Deborah L Miller; Lucas Bortel; Kenneth C Lasseter; Barnali Pramanik; Caroline Cilissen; Qi Liu; Lida Liu; Boyd B Scott; Deborah Panebianco; Yu Ding; Keith Gottesdiener; John A Wagner;
展开▼
作者单位

展开▼
年(卷),期 2013(75),5
年度 2013
页码 1240–1254
总页数 15
原文格式 PDF
正文语种
中图分类药学;
关键词
cathepsin K inhibitor odanacatib osteoporosis pharmacodynamics pharmacokinetics;

机译：组织蛋白酶K抑制剂;奥达那替尼;骨质疏松症;药效学;药代动力学;

相似文献

外文文献
中文文献
专利

1. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: Safety, tolerability, pharmacokinetics and pharmacodynamics - results from single oral dose studies in healthy volunteers [J] . StochS.A., ZajicS., StoneJ.A., British Journal of Clinical Pharmacology . 2013,第5期

机译：Odanacatib，一种选择性的组织蛋白酶K抑制剂，可治疗骨质疏松症：安全性，耐受性，药代动力学和药效学-来自健康志愿者的单次口服剂量研究结果
2. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics – results from single oral dose studies in healthy volunteers [J] . S. Aubrey Stoch, Stefan Zajic, Julie A. Stone, British journal of clinical pharmacology . 2013,第5期

机译：Odanacatib，一种选择性的组织蛋白酶K抑制剂，可治疗骨质疏松症：安全性，耐受性，药代动力学和药效学–健康志愿者单次口服剂量研究的结果
3. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics – results from single oral dose studies in healthy volunteers [J] . S. Aubrey Stoch, Stefan Zajic, Julie A. Stone, British journal of clinical pharmacology . 2013,第5期

机译：Odanacatib，一种选择性的组织蛋白酶K抑制剂，可治疗骨质疏松症：安全性，耐受性，药代动力学和药效学–健康志愿者单次口服剂量研究的结果
4. Safety, tolerability, pharmacodynamics and pharmacokinetics following single subcutaneous dosesof a teverelix depot formulation in healthy male volunteers [C] . C. MacLean, F. Larsen, R. Piechatzek, Annual meeting exposition of the Controlled Release Society . 2005

机译：在健康男性志愿者中单次皮下注射Teverelix储库制剂后的安全性，耐受性，药效动力学和药代动力学
5. Propafenone pharmacokinetics: GLC-ECD analysis; metabolic induction by phenobarbital in nonsmoking and smoking healthy volunteers; protein binding; pharmacodynamics in patients [D] . Chan, Grace Lap-Yu 1989

机译：普罗帕酮药代动力学：GLC-ECD分析；非吸烟和吸烟健康志愿者的苯巴比妥诱导代谢；蛋白质结合；患者的药效学
6. Safety tolerability pharmacokinetics and pharmacodynamics of single oral doses of BI 187004 an inhibitor of 11beta-hydroxysteroid dehydrogenase-1 in healthy male volunteers with overweight or obesity [O] . Susanna Bianzano, Tim Heise, Arvid Jungnik, 2021

机译：单次口服剂量乳头剂量的安全性耐受性药代动力学和药效学11beta-羟类脱氢酶-1的抑制剂具有超重或肥胖的健康男性志愿者
7. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics: results from single oral dose studies in healthy volunteers [O] . Stoch, S Aubrey, Zajic, Stefan, Stone, Julie A, 2013

机译：Odanacatib，一种治疗骨质疏松症的选择性组织蛋白酶K抑制剂：安全性，耐受性，药代动力学和药效学：健康志愿者单次口服剂量研究的结果

Odanacatib a selective cathepsin K inhibitor to treat osteoporosis: safety tolerability pharmacokinetics and pharmacodynamics – results from single oral dose studies in healthy volunteers

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅